XML 46 R33.htm IDEA: XBRL DOCUMENT v3.10.0.1
Fair Value Disclosures (Tables)
9 Months Ended
Aug. 31, 2018
Fair Value Disclosures [Abstract]  
Financial Assets and Liabilities Accounted for at Fair Value on Recurring Basis
The following is a summary of our financial assets and liabilities that are accounted for at fair value on a recurring basis, excluding Investments at fair value based on net asset value (“NAV”) of $325.3 million and $215.4 million at August 31, 2018 and November 30, 2017, respectively, by level within the fair value hierarchy (in thousands):
 
August 31, 2018
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,881,376

 
$
72,569

 
$
48,045

 
$

 
$
2,001,990

Corporate debt securities

 
2,286,852

 
9,651

 

 
2,296,503

Collateralized debt obligations and collateralized loan obligations

 
82,339

 
23,601

 

 
105,940

U.S. government and federal agency securities
2,876,669

 
45,889

 

 

 
2,922,558

Municipal securities

 
749,616

 

 

 
749,616

Sovereign obligations
1,319,415

 
666,745

 

 

 
1,986,160

Residential mortgage-backed securities

 
1,894,533

 
4,954

 

 
1,899,487

Commercial mortgage-backed securities

 
791,449

 
23,916

 

 
815,365

Other asset-backed securities

 
263,967

 
69,305

 

 
333,272

Loans and other receivables

 
1,455,496

 
48,985

 

 
1,504,481

Derivatives
6,644

 
3,496,790

 
3,137

 
(3,331,143
)
 
175,428

Investments at fair value

 

 
79,539

 

 
79,539

Total financial instruments owned, excluding Investments at fair value based on NAV
$
6,084,104

 
$
11,806,245

 
$
311,133

 
$
(3,331,143
)
 
$
14,870,339

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,312,412

 
$
1,507

 
$
413

 
$

 
$
1,314,332

Corporate debt securities

 
1,375,530

 
1,557

 

 
1,377,087

U.S. government and federal agency securities
1,127,608

 

 

 

 
1,127,608

Sovereign obligations
1,513,237

 
958,998

 
55

 

 
2,472,290

Commercial mortgage-backed securities

 

 
70

 

 
70

Loans

 
1,136,579

 
8,661

 

 
1,145,240

Derivatives
4,976

 
4,125,994

 
12,134

 
(3,451,531
)
 
691,573

Total financial instruments sold, not yet purchased
$
3,958,233

 
$
7,598,608

 
$
22,890

 
$
(3,451,531
)
 
$
8,128,200

Long-term debt
$

 
$
545,927

 
$
163,630

 
$

 
$
709,557

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
 
November 30, 2017
 
Level 1
 
Level 2
 
Level 3
 
Counterparty and
Cash Collateral
Netting (1)
 
Total
Assets:
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,801,453

 
$
57,091

 
$
22,009

 
$

 
$
1,880,553

Corporate debt securities

 
3,261,300

 
26,036

 

 
3,287,336

Collateralized debt obligations and collateralized loan obligations

 
139,166

 
30,004

 

 
169,170

U.S. government and federal agency securities
1,269,230

 
39,443

 

 

 
1,308,673

Municipal securities

 
710,513

 

 

 
710,513

Sovereign obligations
1,381,552

 
1,035,907

 

 

 
2,417,459

Residential mortgage-backed securities

 
1,453,294

 
26,077

 

 
1,479,371

Commercial mortgage-backed securities

 
508,115

 
12,419

 

 
520,534

Other asset-backed securities

 
217,111

 
61,129

 

 
278,240

Loans and other receivables

 
1,620,581

 
47,304

 

 
1,667,885

Derivatives
160,168

 
3,248,586

 
9,295

 
(3,254,216
)
 
163,833

Investments at fair value

 
946

 
93,454

 

 
94,400

Total financial instruments owned, excluding Investments at fair value based on NAV
$
4,612,403

 
$
12,292,053

 
$
327,727

 
$
(3,254,216
)
 
$
13,977,967

Securities received as collateral
$
103

 
$

 
$

 
$

 
$
103

 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
1,456,675

 
$
32,122

 
$
48

 
$

 
$
1,488,845

Corporate debt securities

 
1,688,825

 
522

 

 
1,689,347

U.S. government and federal agency securities
1,430,737

 

 

 

 
1,430,737

Sovereign obligations
1,216,643

 
956,992

 

 

 
2,173,635

Commercial mortgage-backed securities

 

 
105

 

 
105

Loans

 
1,148,824

 
3,486

 

 
1,152,310

Derivatives
247,919

 
3,399,239

 
16,041

 
(3,426,249
)
 
236,950

Total financial instruments sold, not yet purchased
$
4,351,974

 
$
7,226,002

 
$
20,202

 
$
(3,426,249
)
 
$
8,171,929

Short-term borrowings
$

 
$
23,324

 
$

 
$

 
$
23,324

Long-term debt
$

 
$
606,956

 
$

 
$

 
$
606,956

Obligation to return securities received as collateral
$
103

 
$

 
$

 
$

 
$
103

(1)
Represents counterparty and cash collateral netting across the levels of the fair value hierarchy for positions with the same counterparty.
Investments Measured at Fair Value Based on Net Asset Value Per Share
The following tables present information about our investments in entities that have the characteristics of an investment company (in thousands):
 
August 31, 2018
 
Fair Value (1)
 
Unfunded
Commitments
 
Redemption Frequency
(if currently eligible)
Equity Long/Short Hedge Funds (2)
$
16,606

 
$

 
Monthly, Quarterly
Fixed Income and High Yield Hedge Funds (3)
219

 

 
Fund of Funds (4)
175

 

 
Equity Funds (5)
36,702

 
20,209

 
Commodity Funds (6)
10,228

 

 
Multi-asset Funds (7)
261,350

 

 
Total
$
325,280

 
$
20,209

 
 
 
November 30, 2017
 
Fair Value (1)
 
Unfunded
Commitments
 
Redemption Frequency
(if currently eligible)
Equity Long/Short Hedge Funds (2)
$
33,176

 
$

 
Monthly, Quarterly
Fixed Income and High Yield Hedge Funds (3)
417

 

 
Fund of Funds (4)
189

 

 
Equity Funds (5)
26,798

 
19,084

 
Multi-asset Funds (7)
154,805

 

 
Total
$
215,385

 
$
19,084

 
 
(1)
Where fair value is calculated based on NAV, fair value has been derived from each of the funds’ capital statements.
(2)
This category includes investments in hedge funds that invest, long and short, primarily in equity securities in domestic and international markets in both the public and private sectors. At August 31, 2018 and November 30, 2017, approximately 2% and 1%, respectively, of the fair value of investments in this category are classified as being in liquidation.
(3)
This category includes investments in funds that invest in loans secured by a first trust deed on property, domestic and international public high yield debt, private high yield investments, senior bank loans, public leveraged equities, distressed debt and private equity investments. There are no redemption provisions.
(4)
This category includes investments in fund of funds that invest in various private equity funds. The investments in this category are managed by us and have no redemption provisions. These investments are gradually being liquidated or we have requested redemption, however, we are unable to estimate when these funds will be received.
(5)
At August 31, 2018 and November 30, 2017, the investments in this category include investments in equity funds that invest in the equity of various U.S. and foreign private companies in the energy, technology, internet service and telecommunication service industries. These investments cannot be redeemed; instead, distributions are received through the liquidation of the underlying assets of the funds which are expected to be liquidated in one to ten years.
(6)
This category includes investments in hedge funds that invest, long and short, primarily in commodities. Investments in this category are redeemable with 60 days prior written notice.
(7)
This category includes investments in hedge funds that invest, long and short, primarily in multi-asset securities in domestic and international markets in both the public and private sectors. At August 31, 2018 and November 30, 2017, investments representing approximately 17% and 12%, respectively, of the fair value of investments in this category are redeemable with 30 days prior written notice.
Summary of Changes in Fair Value of Financial Assets and Liabilities Classified as Level 3
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended August 31, 2018 (in thousands):
 
Three Months Ended August 31, 2018
 
 
 
Total gains/losses (realized and unrealized) (1)
 
 
 
 
 
 
 
 
 
Net transfers into/
 (out of) Level 3
 
 
 
For instruments still held at August 31, 2018, changes in unrealized gains/(losses) included in:
 
Balance at
May 31, 2018
 
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
 
Balance at
August 31, 2018
 
earnings (1)
 
other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
42,901

 
$
12,128

 
$
17,652

 
$
(23,010
)
 
$
(302
)
 
$

 
$
(1,324
)
 
$
48,045

 
$
9,468

 
$

Corporate debt securities
28,066

 
1,057

 
507

 
(21,403
)
 
(59
)
 

 
1,483

 
9,651

 
(165
)
 

CDOs and CLOs
30,603

 
567

 
238,281

 
(240,002
)
 
(2,127
)
 

 
(3,721
)
 
23,601

 
(2,338
)
 

RMBS
3,655

 
(66
)
 
72

 
(1,597
)
 
(1
)
 

 
2,891

 
4,954

 
90

 

CMBS
27,239

 
(222
)
 
8

 

 
(1,156
)
 

 
(1,953
)
 
23,916

 
(288
)
 

Other ABS
55,535

 
(2,269
)
 
307,358

 
(290,838
)
 
(4,356
)
 

 
3,875

 
69,305

 
(1,124
)
 

Loans and other receivables
64,036

 
(1,353
)
 
14,932

 
(23,700
)
 
(3,453
)
 

 
(1,477
)
 
48,985

 
1,007

 

Investments at fair value
79,488

 

 
51

 

 

 

 

 
79,539

 

 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
87

 
$
326

 
$

 
$

 
$

 
$

 
$

 
$
413

 
$
(326
)
 
$

Corporate debt securities
522

 
39

 

 

 
996

 

 

 
1,557

 
(39
)
 

Sovereign obligations

 
3

 
(598
)
 
629

 

 

 
21

 
55

 
(124
)
 

CMBS

 
70

 

 

 

 

 

 
70

 
(70
)
 

Loans
12,881

 
(148
)
 
(4,871
)
 
1,787

 

 

 
(988
)
 
8,661

 
149

 

Net derivatives (2)
5,874

 
1,107

 

 

 
1,990

 

 
26

 
8,997

 
(2,090
)
 

Long-term debt
160,626

 
3,004

 

 

 

 

 

 
163,630

 
(2,953
)
 
(51
)
(1)
Realized and unrealized gains/losses are primarily reported in Principal transaction revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the three months ended August 31, 2017 (in thousands):
 
Three Months Ended August 31, 2017
 
Balance at
May 31, 2017
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at August 31, 2017
 
Change in
unrealized gains/
(losses) relating
to instruments
still held at
August 31, 2017 (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
20,548

 
$
4,344

 
$
4

 
$
(645
)
 
$
(55
)
 
$

 
$
(2,022
)
 
$
22,174

 
$
4,319

Corporate debt securities
24,727

 
(2,350
)
 
5,901

 
(5,551
)
 
(31
)
 

 
2,319

 
25,015

 
(2,224
)
CDOs and CLOs
27,255

 
(6,119
)
 
52,918

 
(36,564
)
 
245

 

 
468

 
38,203

 
(3,552
)
RMBS
33,032

 
(263
)
 
494

 
(732
)
 
(291
)
 

 
(11,591
)
 
20,649

 
188

CMBS
16,263

 
(125
)
 

 
(676
)
 
(637
)
 

 
2,811

 
17,636

 
(161
)
Other ABS
43,349

 
(6,454
)
 
5,798

 
(3,789
)
 
(2,924
)
 

 
32,966

 
68,946

 
(3,570
)
Loans and other receivables
49,365

 
15,261

 
9,265

 
(5,854
)
 
(8,249
)
 

 
2,868

 
62,656

 
14,005

Investments at fair value
89,006

 
1,703

 

 

 
(292
)
 

 

 
90,417

 
1,703

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
354

 
$
107

 
$
(369
)
 
$
27

 
$

 
$

 
$

 
$
119

 
$
(92
)
Corporate debt securities
522

 

 

 

 

 

 

 
522

 

CMBS
70

 
(35
)
 

 

 

 

 

 
35

 
(35
)
Loans
4,967

 
(3,071
)
 

 
333

 

 

 
1,056

 
3,285

 
3,018

Net derivatives (2)
3,022

 
(2,980
)
 

 

 
5,040

 

 

 
5,082

 
(2,474
)
(1)
Realized and unrealized gains/losses are reported in Principal transaction revenues in our Consolidated Statements of Earnings.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the nine months ended August 31, 2017 (in thousands):
 
Nine Months Ended August 31, 2017
 
Balance at
November 30, 2016
 
Total gains/losses (realized and unrealized) (1)
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
Net transfers into/
(out of) Level 3
 
Balance at
August 31, 2017
 
Change in
unrealized gains/
(losses) relating
to instruments
still held at
August 31, 2017 (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
21,739

 
$
3,416

 
$
945

 
$
(1,502
)
 
$
(356
)
 
$

 
$
(2,068
)
 
$
22,174

 
$
2,689

Corporate debt securities
25,005

 
(3,280
)
 
19,610

 
(18,364
)
 
(1,724
)
 

 
3,768

 
25,015

 
(3,424
)
CDOs and CLOs
54,354

 
(13,902
)
 
65,523

 
(72,122
)
 
239

 

 
4,111

 
38,203

 
(3,685
)
Municipal securities
27,257

 
(1,547
)
 

 
(25,710
)
 

 

 

 

 

RMBS
38,772

 
(1,446
)
 
113,391

 
(125,731
)
 
(572
)
 

 
(3,765
)
 
20,649

 
(2,005
)
CMBS
20,580

 
(1,180
)
 
2,033

 
(5,199
)
 
(985
)
 

 
2,387

 
17,636

 
(952
)
Other ABS
40,911

 
(15,338
)
 
67,611

 
(4,121
)
 
(16,891
)
 

 
(3,226
)
 
68,946

 
(8,872
)
Loans and other receivables
81,872

 
27,709

 
84,342

 
(83,791
)
 
(23,241
)
 

 
(24,235
)
 
62,656

 
16,294

Investments at fair value
96,369

 
4,698

 
300

 
(10,119
)
 
(831
)
 

 

 
90,417

 
6,721

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
313

 
$
134

 
$
(355
)
 
$
27

 
$

 
$

 
$

 
$
119

 
$
(92
)
Corporate debt securities
523

 
(1
)
 

 

 

 

 

 
522

 
1

CMBS

 
35

 

 

 

 

 

 
35

 
(35
)
Loans
378

 
1,604

 
(364
)
 
333

 

 

 
1,334

 
3,285

 
(1,583
)
Net derivatives (2)
3,441

 
(2,854
)
 

 

 
5,162

 
404

 
(1,071
)
 
5,082

 
(2,333
)
Other secured financings
418

 
(418
)
 

 

 

 

 

 

 

(1)
Realized and unrealized gains/losses are reported in Principal transaction revenues in our Consolidated Statements of Earnings.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
The following is a summary of changes in fair value of our financial assets and liabilities that have been categorized within Level 3 of the fair value hierarchy for the nine months ended August 31, 2018 (in thousands):
 
Nine Months Ended August 31, 2018
 
 
 
Total gains/losses (realized and unrealized) (1)
 
 
 
 
 
 
 
 
 
Net transfers into/
 (out of) Level 3
 
 
 
For instruments still held at August 31, 2018, changes in unrealized gains/(losses) included in:
 
Balance at November 30, 2017
 
 
Purchases
 
Sales
 
Settlements
 
Issuances
 
 
Balance at August 31, 2018
 
earnings (1)
 
other comprehensive income (1)
Assets:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments owned:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
22,009

 
$
30,098

 
$
35,993

 
$
(39,008
)
 
$
(2,082
)
 
$

 
$
1,035

 
$
48,045

 
$
25,475

 
$

Corporate debt securities
26,036

 
1,090

 
22,204

 
(38,553
)
 
(2,066
)
 

 
940

 
9,651

 
(1,738
)
 

CDOs and CLOs
30,004

 
(2,323
)
 
242,864

 
(249,691
)
 
(5,859
)
 

 
8,606

 
23,601

 
(5,533
)
 

RMBS
26,077

 
(7,334
)
 
2,018

 
(12,621
)
 
(6
)
 

 
(3,180
)
 
4,954

 
316

 

CMBS
12,419

 
(1,236
)
 
1,720

 
(548
)
 
(5,415
)
 

 
16,976

 
23,916

 
(2,272
)
 

Other ABS
61,129

 
(7,528
)
 
523,045

 
(495,055
)
 
(12,281
)
 

 
(5
)
 
69,305

 
(3,307
)
 

Loans and other receivables
47,304

 
(2,812
)
 
104,009

 
(98,733
)
 
(14,610
)
 

 
13,827

 
48,985

 
(3,769
)
 

Investments at fair value
93,454

 
417

 
2,291

 
(17,569
)
 

 

 
946

 
79,539

 
(177
)
 

Liabilities:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Financial instruments sold, not yet purchased:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Corporate equity securities
$
48

 
$
365

 
$

 
$

 
$

 
$

 
$

 
$
413

 
$
(365
)
 
$

Corporate debt securities
522

 
39

 

 

 
996

 

 

 
1,557

 
(39
)
 

Sovereign obligations

 
3

 
(598
)
 
629

 

 

 
21

 
55

 
(124
)
 

CMBS
105

 
(35
)
 

 

 

 

 

 
70

 
(70
)
 

Loans
3,486

 
(1,059
)
 
(15,702
)
 
19,409

 

 

 
2,527

 
8,661

 
1,059

 

Net derivatives (2)
6,746

 
(1,034
)
 
(6
)
 

 
2,984

 
296

 
11

 
8,997

 
(2,660
)
 

Long-term debt

 
(25,078
)
 

 

 

 
81,284

 
107,424

 
163,630

 
36,921

 
(11,843
)
(1)
Realized and unrealized gains/losses are primarily reported in Principal transaction revenues in our Consolidated Statements of Earnings. Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Net derivatives represent Financial instruments owned—Derivatives and Financial instruments sold, not yet purchased—Derivatives.
Quantitative Information about Significant Unobservable Inputs Used in Level 3 Fair Value Measurements
The tables below present information on the valuation techniques, significant unobservable inputs and their ranges for our financial assets and liabilities, subject to threshold levels related to the market value of the positions held, measured at fair value on a recurring basis with a significant Level 3 balance. The range of unobservable inputs could differ significantly across different firms given the range of products across different firms in the financial services sector. The inputs are not representative of the inputs that could have been used in the valuation of any one financial instrument (i.e., the input used for valuing one financial instrument within a particular class of financial instruments may not be appropriate for valuing other financial instruments within that given class). Additionally, the ranges of inputs presented below should not be construed to represent uncertainty regarding the fair values of our financial instruments; rather, the range of inputs is reflective of the differences in the underlying characteristics of the financial instruments in each category.
For certain categories, we have provided a weighted average of the inputs allocated based on the fair values of the financial instruments comprising the category. We do not believe that the range or weighted average of the inputs is indicative of the reasonableness of uncertainty of our Level 3 fair values. The range and weighted average are driven by the individual financial instruments within each category and their relative distribution in the population. The disclosed inputs when compared with the inputs as disclosed in other periods should not be expected to necessarily be indicative of changes in our estimates of unobservable inputs for a particular financial instrument as the population of financial instruments comprising the category will vary from period to period based on purchases and sales of financial instruments during the period as well as transfers into and out of Level 3 each period.
August 31, 2018
Financial Instruments Owned:
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
41,038

 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
Market approach
 
Price
 
$3-$75
 
$
25

 
 
 
 
 
 
Underlying stock price
 
$1-$11
 
$
9

Corporate debt securities
 
$
9,651

 
Market approach
 
Discount rate/yield
 
19%
 

 
 
 
 
 
 
Estimated recovery percentage
 
46%
 

 
 
 
 
 
 
Price
 
$10
 

 
 
 
 
 
 
Comparable asset price
 
$101
 

CDOs and CLOs
 
$
23,601

 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
1%-2%
 
2
%
 
 
 
 
 
 
Loss severity
 
30%
 

 
 
 
 
 
 
Discount rate/yield
 
5%-41%
 
16
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
2%
 

RMBS
 
$
4,954

 
Discounted cash flows
 
Cumulative loss rate
 
23%
 

 
 
 
 
 
 
Duration (years)
 
15
 

 
 
 
 
 
 
Discount rate/yield
 
9%
 

 
 
 
 
Market approach
 
Price
 
$100
 

CMBS
 
$
23,916

 
Discounted cash flows
 
Cumulative loss rate
 
8%-84%
 
33
%
 
 
 
 
 
 
Duration (years)
 
0-3
 
1

 
 
 
 
 
 
Discount rate/yield
 
3%-38%
 
12
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
26%
 

 
 
 
 
 
 
Price
 
$49
 

Other ABS
 
$
69,305

 
Discounted cash flows
 
Cumulative loss rate
 
0%-29%
 
18
%
 
 
 
 
 
 
Duration (years)
 
1-5
 
2

 
 
 
 
 
 
Discount rate/yield
 
5%-12%
 
7
%
 
 
 
 
Market approach
 
Price
 
$100
 

Loans and other receivables
 
$
48,985

 
Market approach
 
Estimated recovery percentage
 
0%
 

 
 
 
 
 
 
Price
 
$50-$100
 
$
95

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
57%-107%
 
88
%
Derivatives
 
$
3,137

 
 
 
 
 
 
 
 
Total return swaps
 
 
 
Market approach
 
Price
 
$100
 

Investments at fair value
 
$
79,539

 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Price
 
$3-$250
 
$
105

Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
Corporate debt securities
 
$
1,557

 
Market approach
 
Estimated recovery percentage
 
53%
 

Loans
 
$
8,661

 
Market approach
 
Estimated recovery percentage
 
0%
 

 
 
 
 
 
 
Price
 
$50
 

Derivatives
 
$
12,134

 
 
 
 
 
 
 
 
Equity options
 
 
 
Option model/default rate
 
Default probability
 
0%
 

Unfunded commitments
 
 
 
Market approach
 
Price
 
$99
 

Total return swaps
 
 
 
Market approach
 
Price
 
$95-$100
 
$
97

Variable funding note swaps
 
 
 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
2%
 

 
 
 
 
 
 
Loss severity
 
30%
 

 
 
 
 
 
 
Discount rate/yield
 
41%
 

Long-term debt
 
 
 
 
 
 
 
 
 
 
Structured notes
 
$
163,630

 
Market approach
 
Price
 
$70-$100
 
$
80

 
 
 
 
 
 
Price
 
€80-€112
 
€ 96
November 30, 2017
Financial Instruments Owned:
 
Fair Value
(in thousands)
 
Valuation Technique
 
Significant Unobservable Input(s)
 
Input / Range
 
Weighted
Average
Corporate equity securities
 
$
18,109

 
 
 
 
 
 
 
 
Non-exchange-traded securities
 
Market approach
 
Price
 
$3-$75
 
$
33

 
 
 
 
 
 
Underlying stock price
 
$6
 

 
 
 
 
Comparable pricing
 
Comparable asset price
 
$7
 

Corporate debt securities
 
$
26,036

 
Convertible bond model
 
Discount rate/yield
 
8%
 

 
 
 
 

 
Volatility
 
40%
 

 
 
 
 
Market approach
 
Estimated recovery percentage
 
17%
 

 
 
 
 
 
 
Price
 
$10
 

CDOs and CLOs
 
$
30,004

 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
2%
 

 
 
 
 
 
 
Loss severity
 
25%-30%
 
26
%
 
 
 
 
 
 
Discount rate/yield
 
3%-26%
 
12
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
8%-40%
 
22
%
RMBS
 
$
26,077

 
Discounted cash flows
 
Cumulative loss rate
 
3%-19%
 
10
%
 
 
 
 
 
 
Duration (years)
 
2-4
 
3

 
 
 
 
 
 
Discount rate/yield
 
6%-10%
 
8
%
CMBS
 
$
12,419

 
Discounted cash flows
 
Cumulative loss rate
 
8%-65%
 
44
%
 
 
 
 
 
 
Duration (years)
 
1-3
 
2

 
 
 
 
 
 
Discount rate/yield
 
2%-26%
 
12
%
 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
26%-32%
 
28
%
 
 
 
 
 
 
Price
 
$52-$56
 
$
54

Other ABS
 
$
61,129

 
Discounted cash flows
 
Cumulative loss rate
 
0%-33%
 
23
%
 
 
 
 
 
 
Duration (years)
 
1-6
 
2

 
 
 
 
 
 
Discount rate/yield
 
5%-39%
 
9
%
 
 
 
 
Market approach
 
Price
 
$100
 

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
14%
 

Loans and other receivables
 
$
46,121

 
Market approach
 
Estimated recovery percentage
 
76%
 

 
 
 
 
 
 
Price
 
$54-$100
 
$
95

 
 
 
 
Scenario analysis
 
Estimated recovery percentage
 
13%-107%
 
78
%
Derivatives
 
$
9,295

 
 
 
 
 
 
 
 
Total return swaps
 
 
 
Market approach
 
Price
 
$101-$106
 
$
103

Interest rate swaps
 
 
 
Market approach
 
Credit spread
 
800 bps
 

Investments at fair value
 
$
77,423

 
 
 
 
 
 
 
 
Private equity securities
 
 
 
Market approach
 
Transaction level
 
$3-$250
 
$
172

 
 
 
 
 
 
Price
 
$7
 

Financial Instruments Sold, Not Yet Purchased:
 
 
 
 
 
 
 
 
Derivatives
 
$
16,041

 
 
 
 
 
 
 
 
Equity options
 
 
 
Option model/default rate
 
Default probability
 
0%
 

Unfunded commitments
 
 
 
Market approach
 
Price
 
$99
 

Total return swaps
 
 
 
Market approach
 
Price
 
$101-$106
 
$
103

Variable funding note swaps
 
 
 
Discounted cash flows
 
Constant prepayment rate
 
20%
 

 
 
 
 
 
 
Constant default rate
 
2%
 

 
 
 
 
 
 
Loss severity
 
25%
 

 
 
 
 
 
 
Discount rate/yield
 
26%
 

Summary of Gains (Losses) Due to Changes in Instrument Specific Credit Risk and Summary of Contractual Principal Exceeds Fair Value for Loans and Other Receivables
The following is a summary of gains (losses) due to changes in instrument specific credit risk on loans, other receivables and debt instruments and gains (losses) due to other changes in fair value on Long-term debt and Short-term borrowings measured at fair value under the fair value option (in thousands):
 
Three Months Ended 
 August 31,
 
Nine Months Ended 
 August 31,
 
2018
 
2017
 
2018
 
2017
Financial instruments owned:
 
 
 
 
 
 
 
Loans and other receivables
$
14,002

 
$
24,846

 
$
7,495

 
$
27,715

Financial instruments sold:
 
 
 
 
 
 
 
Loans
$
(2,708
)
 
$
3,436

 
$
(2,467
)
 
$
(7,286
)
Loan commitments
(1,695
)
 
82

 
(1,964
)
 
229

Long-term debt:
 
 
 
 
 
 
 
Changes in instrument specific credit risk (1)
$
1,401

 
$
5,638

 
$
19,986

 
$
(14,141
)
Other changes in fair value (2)
(6,842
)
 
(1,854
)
 
33,626

 
2,786

Short-term borrowings:
 
 
 
 
 
 
 
Changes in instrument specific credit risk (1)
$

 
$
19

 
$

 
$
1

Other changes in fair value (2)

 
(2,570
)
 

 
(37
)
(1)
Changes in instrument-specific credit risk related to structured notes are included in our Consolidated Statements of Comprehensive Income, net of tax.
(2)
Other changes in fair value are included in Principal transactions revenues in our Consolidated Statements of Earnings.
The following is a summary of the amount by which contractual principal exceeds fair value for loans and other receivables, long-term debt and short-term borrowings measured at fair value under the fair value option (in thousands):
 
August 31, 2018
 
November 30, 2017
Financial instruments owned:
 
 
 
Loans and other receivables (1)
$
896,470

 
$
752,076

Loans and other receivables on nonaccrual status and/or 90 days or greater past due (1) (2)
167,355

 
159,462

Long-term debt and short-term borrowings
89,345

 
32,839

(1)
Interest income is recognized separately from other changes in fair value and is included in Interest revenues in our Consolidated Statements of Earnings.
(2)
Amounts include loans and other receivables 90 days or greater past due by which contractual principal exceeds fair value of $33.7 million and $38.7 million at August 31, 2018 and November 30, 2017, respectively.